A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies

Inclusion Criteria: * Patients must have histologically documented AML, ALL, MDS, CML, * Identification of haploidentical donor * LVEF \> 45% corrected * DLCO \> 50% predicted * Serum Creatinine \<= 2 mg/dL * Bilirubin \< 2 x ULN * AST, ALT \< 2 x ULN * Age ≤ 65 years * Performance Status 0-1 Exclusion Criteria: * Patients relapsing \<6 months after autologous SCT are not eligible. * Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection * No HIV disease * Non-pregnant and non-nursing